Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2018
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2018
SUMMARY
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 13 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 3 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Central Nervous System, Genetic Disorders, Gastrointestinal, Hematological Disorders, Metabolic Disorders and Oncology which include indications Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Muscular Dystrophy, Sarcopenia, Anemia, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type I, Crohn's Disease (Regional Enteritis), Insulin Resistance, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis and Thalassemia.
The latest report GrowthDifferentiation Factor 8%li%Pipeline Review, H2 2018, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 13 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 3 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Central Nervous System, Genetic Disorders, Gastrointestinal, Hematological Disorders, Metabolic Disorders and Oncology which include indications Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Muscular Dystrophy, Sarcopenia, Anemia, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type I, Crohn's Disease (Regional Enteritis), Insulin Resistance, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis and Thalassemia.
The latest report GrowthDifferentiation Factor 8%li%Pipeline Review, H2 2018, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Amgen Inc
Biogen Inc
Bioleaders Corp
F. Hoffmann-La Roche Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
ACE-083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACE-2494 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLS-ILB-MD1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-2477 + trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRK-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talditercept alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
Featured News & Press Releases
Aug 31, 2018: Pfizer to abort trials of Duchenne muscular dystrophy drug
Jul 23, 2018: Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease at the 2018 Annual Meeting of the Peripheral Nerve Society
Jul 12, 2018: Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
Jul 09, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Jul 05, 2018: Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer
Jun 28, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
Jun 26, 2018: Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society
Jun 15, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association
Jun 04, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting
May 31, 2018: Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
May 17, 2018: Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association
May 01, 2018: Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
Apr 26, 2018: Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting
Apr 26, 2018: Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting
Apr 15, 2018: Genentech to Present Phase Ib/II Study Results of RG6206
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Amgen Inc
Biogen Inc
Bioleaders Corp
F. Hoffmann-La Roche Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
ACE-083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACE-2494 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLS-ILB-MD1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-2477 + trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRK-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talditercept alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
Featured News & Press Releases
Aug 31, 2018: Pfizer to abort trials of Duchenne muscular dystrophy drug
Jul 23, 2018: Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease at the 2018 Annual Meeting of the Peripheral Nerve Society
Jul 12, 2018: Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
Jul 09, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Jul 05, 2018: Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer
Jun 28, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
Jun 26, 2018: Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society
Jun 15, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association
Jun 04, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting
May 31, 2018: Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
May 17, 2018: Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association
May 01, 2018: Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
Apr 26, 2018: Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting
Apr 26, 2018: Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting
Apr 15, 2018: Genentech to Present Phase Ib/II Study Results of RG6206
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Acceleron Pharma Inc, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by Bioleaders Corp, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by PeptiDream Inc, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Scholar Rock Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Acceleron Pharma Inc, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by Bioleaders Corp, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by PeptiDream Inc, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Scholar Rock Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Acceleron Pharma Inc
Amgen Inc
Biogen Inc
Bioleaders Corp
F. Hoffmann-La Roche Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Acceleron Pharma Inc
Amgen Inc
Biogen Inc
Bioleaders Corp
F. Hoffmann-La Roche Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
